Tarsus Pharmaceuticals 

Yahoo Finance • 20 days ago

Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade

Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals(NASDAQ:TARS), reported the direct sale of 12,274 shares of common stock in multiple open-market transactions between March 17 and March 19, 2026, as disclosed in... Full story

Yahoo Finance • 22 days ago

Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?

On February 17, 2026, Paradigm Biocapital Advisors LP disclosed a buy of 750,000 shares of Olema Pharmaceuticals(NASDAQ:OLMA) in Q4 2025, an estimated $13.35 million trade based on quarter-end pricing. What happened According to a Securi... Full story

Yahoo Finance • last month

Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) is among the 10 Fastest Growing NASDAQ Stocks to Buy.Oppenheimer Raises Its Price Target on Tarsus Pharmaceuticals, Inc. (TARS) to $105 and Maintains an Outperform Rating On February 25, 2026, Op... Full story

Yahoo Finance • last month

These Growth Stocks Form Classic Cup Bases. Here's Where To Buy.

Two eyedrops stocks are forming cup bases on their charts and one has earnings coming up. A data center play is in a cup base buy zone. Continue Reading... Full story

Yahoo Finance • 2 months ago

Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Tarsus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Moby Strategic Performance and Market Transformation Delivered $450 million in full-year net sales for 2025, establishing XDEMVY as a breakout therapeutic and the company as a... Full story

Yahoo Finance • 5 months ago

Tarsus to Participate in Upcoming Investor Conference

IRVINE, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the BTIG 5th Annual Ophthalmology Day on Monday, December 1st, at 10:45... Full story

Yahoo Finance • 5 months ago

Tarsus outlines $140M–$145M Q4 sales target while expanding XDEMVY adoption and pipeline progress

Earnings Call Insights: Tarsus Pharmaceuticals (TARS) Q3 2025 MANAGEMENT VIEW * CEO Bobak Azamian highlighted the exceptional performance of XDEMVY, stating, "We delivered more than 103,000 bottles of XDEMVY to patients and recognized... Full story

Yahoo Finance • 5 months ago

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring strong commercial momentum Management to... Full story

Yahoo Finance • 5 months ago

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025... Full story

Yahoo Finance • 6 months ago

Is Waystar a Buy After Investment Company Capricorn Fund Managers Makes the Stock Its Top Holding?

Key Points Capricorn Fund Managers initiated a position in Waystar with 505,122 shares acquired, estimated at ~$19.15 million based on the average price during Q3 2025. The Waystar stake represents 6.4% of Capricorn Fund Managers' 13F rep... Full story

Yahoo Finance • 7 months ago

Interesting TARS Put And Call Options For November 21st

Investors in Tarsus Pharmaceuticals Inc (Symbol: TARS) saw new options begin trading this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the TARS options chain for the new... Full story

Yahoo Finance • 8 months ago

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Wells Fargo 20th Annual Healthcare Confe... Full story

Yahoo Finance • 8 months ago

This Eye Treatment Stock Sees Sales Spike 152% As Biotech Leaders Shine

Biotech stocks are performing well in the stock market in August and a few in the IBD 50 have formed bases with clear buy points. Continue Reading View Comments... Full story

Yahoo Finance • 8 months ago

Tarsus targets 95,000–100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum

Earnings Call Insights: Tarsus Pharmaceuticals (TARS) Q2 2025 MANAGEMENT VIEW * CEO Bobak R. Azamian highlighted that "we delivered record-breaking results of more than $100 million in net sales and approximately 91,000 bottles dispens... Full story

Yahoo Finance • 8 months ago

Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements

Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded base and depth of prescribers and le... Full story

Yahoo Finance • 8 months ago

Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025

IRVINE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Wednesday, August 6, 2025, to report its second quarter 202... Full story

Yahoo Finance • 11 months ago

Tarsus Pharmaceuticals, Inc. (TARS): Among the Best Breakout Stocks to Buy According to Analysts

We recently published a list of 11 Best Breakout Stocks to Buy According to Analysts. In this article, we are going to take a look at where Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) stands against other best breakout stocks to buy accordi... Full story

Yahoo Finance • 12 months ago

Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual Meeting

IRVINE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will present four distinct data sets highlighting the global prevalence and real-world patient burden of Demodex blepharitis, as well as the i... Full story

Yahoo Finance • last year

Tarsus Announces Pricing of Upsized $125.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the pricing of an upsized underwritten public offering of 2,808,988 shares of its common stock at... Full story

Yahoo Finance • last year

Tarsus Announces Proposed $100.0 Million Public Offering

IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) (the “Company” or “Tarsus”) today announced the commencement of an underwritten public offering of $100.0 million of shares of its common stoc... Full story